ABCL
ABCL
Positions held
Your positionsABCL isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · What Could Go Wrong With Recursion Pharmaceuticals Stock?
2026-10-08 · AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
2026-10-01 · AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
2026-10-01 · AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
2026-09-30 · Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
2026-09-29 · JPMorgan Initiates AbCellera Biologics at Overweight With $17 Price Target
2026-09-22 · ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
2026-09-16 · AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
2026-09-02 · AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
2026-08-16 · AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity
Price (daily)
Full chart · RSI · MACD · patterns